BSX
Boston Scientific Corporation92.95
+0.76+0.82%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Defends EP, WATCHMAN amid concerns
Q&A dismissed sequential U.S. EP softness concerns, revealing management views Q4 market growth at 18-20%—not 25%—with Boston Scientific's 35% surge exceeding plans and trouncing rivals. They anticipate modest PFA share loss to new entrants yet clear leadership by 2026-end in a 15% market, limited by lab capacity. WATCHMAN unscathed by rival trials; CHAMPION may show bleeding superiority to sustain concomitant growth. H2 acceleration eyed in urology, neuromod, Endo post-AXIOS. EP dominated peers. Bullish LRP tone intact; watch non-EP ramps.
Key Stats
Market Cap
137.79BP/E (TTM)
49.71Basic EPS (TTM)
1.87Dividend Yield
0%Recent Filings
8-K
New $11B facilities back Penumbra
Boston Scientific entered $3B 5-year revolving credit, $2B 364-day revolver, and $6B delayed-draw term loans maturing 364 days post-Penumbra acquisition close, terminating its prior facility. Facilities support the pending Penumbra deal with Term SOFR-based pricing tied to ratings and a 3.75x leverage covenant, stepping to 4.75x post-qualified acquisition. Leverage covenant flexes for litigation payments up to $1.16B.
8-K
Board adds Smith, Weber; $5B buyback
Boston Scientific expanded its board from 10 to 12 directors on February 18, 2026, appointing finance veteran Cathy Smith (Starbucks CFO) to Audit and Nominating committees, and pharma leader Christophe Weber (Takeda CEO) to Compensation and Risk committees, effective February 23. Board also boosted stock repurchase authorization by $4.0 billion to $5.0 billion total. Fresh expertise bolsters innovation push.
10-K
FY2025 results
Boston Scientific delivered FY2025 net sales of $20.1B, up 19.9% reported (15.8% organic), with Cardiovascular surging 23.2% on Farapulse PFA acceleration and WATCHMAN gains, while MedSurg grew 13.9%. Q4 momentum built through Electrophysiology's rapid PFA adoption, now dominant in the unit. Gross margins held at 69.0% despite ACURATE discontinuation charges; operating income hit $3.6B. Debt stands at $11.4B with $2.8B revolver availability; no buybacks, $1B authorized. No 2026 guidance disclosed. Supply chain disruptions threaten quarterly momentum.
8-K
Fujimori to exit board in 2026
8-K
Q4 sales up 15.9%
Boston Scientific crushed Q4 2025 with $5.286B net sales, up 15.9% reported and 12.7% organic, driven by 18.2% Cardiovascular growth while MedSurg rose 11.7%. Full-year sales hit $20.074B, up 19.9% reported, with adjusted EPS at $3.06. Momentum builds: guides 10.0-11.0% organic growth for 2026. Acquisitions pending.
IPO
Employees
Sector
Industry
BDX
Becton, Dickinson and Company
196.39-3.70
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BRKR
Bruker Corporation
44.96-0.71
BVS
Bioventus Inc.
7.52+0.02
CNMD
CONMED Corporation
39.20-1.12
ENOV
Enovis Corporation
26.07-0.47
EW
Edwards Lifesciences Corporatio
85.32+1.94
MDT
Medtronic plc.
97.72-0.85
SYK
Stryker Corporation
351.69-3.62
TFX
Teleflex Incorporated
124.87-1.85